Related Experiment Video

Updated: Aug 5, 2026

Simultaneous Electrocardiography Recording and Invasive Blood Pressure Measurement in Rats
07:35

Simultaneous Electrocardiography Recording and Invasive Blood Pressure Measurement in Rats

Published on: January 31, 2019

Effects of endothelin-1 and endothelin-3 on blood pressure in conscious hypertensive rats

T X Watanabe1, S Kumagaye, H Nishio

  • 1Peptide Institute, Inc., Protein Research Foundation, Osaka, Japan.

Journal of Cardiovascular Pharmacology
|January 1, 1989
PubMed

Insights

Rat endothelin (ET-3) demonstrated increased vasopressor activity in spontaneously hypertensive rats (SHR). Further research is needed to understand this heightened potency and the causes of hypertension in SHR.

Area of Science:

  • Cardiovascular Physiology
  • Endocrinology
  • Hypertension Research

Background:

  • Endothelin (ET) is a potent vasoconstrictor peptide.
  • Hypertension is a complex cardiovascular condition with various contributing factors.
  • Different rat models exhibit distinct hypertensive mechanisms.

Purpose of the Study:

  • To compare the vasopressor potencies of endothelin in different rat models of hypertension.
  • To investigate the specific activity of rat endothelin (ET-3) in spontaneously hypertensive rats (SHR).

Main Methods:

  • Determination of vasopressor potencies of endothelin in Sprague-Dawley rats (SHR), deoxycorticosterone acetate (DOC)-treated rats, and clipped renal hypertensive rats (CLIP).
  • Administration of rat endothelin (ET-3) to assess its effect on blood pressure in these models.

Main Results:

  • Rat endothelin (ET-3) exhibited significantly greater vasopressor activity in SHR compared to DOC and CLIP hypertensive rats.
  • Variations in endothelin potency were observed across the different hypertensive rat models.

Conclusions:

  • Endothelin-3 plays a more pronounced role in elevating blood pressure in spontaneously hypertensive rats.
  • The underlying mechanisms for the enhanced endothelin potency in SHR require further investigation.
  • Understanding these mechanisms could offer new insights into hypertension pathogenesis.

More Related Videos

Evaluation of Cerebral Blood Flow Autoregulation in the Rat Using Laser Doppler Flowmetry07:12

Evaluation of Cerebral Blood Flow Autoregulation in the Rat Using Laser Doppler Flowmetry

Published on: January 19, 2020

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Related Concept Videos

Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...